Introduction
Granulosa cell tumours (GCTs) of the ovary are relatively uncommon neoplasms, representing approximately 5% of all ovarian malignancies [1, 2] . They exhibit many morphological, biochemical and hormonal features of normal proliferating preovulatory granulosa cells, including both oestrogen and inhibin biosynthesis [3] . GCTs most commonly present during the perimenopausal or early postmenopausal period, with the peak incidence occurring between the ages of 50 and 54 years [1, 2] . Their presentation can include endocrine manifestations, particularly features of oestrogen excess, in postmenopausal women. A much less common juvenile form also occurs and represents approximately 5% of all GCTs [1,2].
Owing to the relative infrequency with which GCTs occur, opportunities to implement randomized clinical trials to evaluate the effects of proposed treatment regimes are limited. The literature reporting the optimum management, molecular profiling and treatment therapies of this tumour type is very modest. In this article, we review the current literature and provide an update on recent developments in GCT research.
Prognostic factors
In contrast to ovarian tumours of epithelial origin, GCTs are considered to be of low malignant potential and are characterized by their slow growth and late recurrence. Stage is clearly the most important prognostic factor. In a recent analysis of 339 women with GCTs, only early-stage disease and age 50 or less were identified as statistically significant predictors of survival [4] . The reported 5-yearsurvival rate for patients with stage I disease ranges from 75%, with the majority of studies demonstrating a survival rate of greater than 90% [1,2]. Recurrence is, however, associated with poor prognosis, with over 80% of patients succumbing to the disease [5] .
A number of recent studies have evaluated histologic features of GCTs for their prognostic significance. GCTs exhibit many features of normal ovarian granulosa cells including expression of the gene encoding the folliclestimulating hormone (FSH) receptor, FSH binding, oestrogen synthesis and expression of the genes encoding the inhibin subunits leading to the synthesis of biologically active inhibin [6] . Anttonen et al. [7] analysed the protein expression of factors that regulate normal granulosa cell Purpose of review Granulosa cell tumours of the ovary are relatively uncommon malignant tumours. Although the majority of patients present with early-stage disease that is curable, approximately 80% of patients with advanced tumours die from recurrent disease. The purpose of this review is to provide the clinician with an update on recent research relevant to granulosa cell tumours.
Recent findings
The measurement of serum inhibin levels is useful in the diagnosis of granulosa cell tumours in postmenopausal women and for monitoring the disease following oophorectomy at any age. Surgery remains the most effective primary treatment, whereas hormonal therapy for patients with advanced stages or recurrent disease has resulted in varying outcomes. The presence of the gsp oncogene and high GATA-4 protein expression in juvenile granulosa cell tumours may provide new prognostic markers. In-vitro testing of a recently discovered tyrosine kinase inhibitor indicates that further developments in this area may provide a novel therapeutic target for the treatment of granulosa cell tumours. Summary Further investigation to determine the molecular changes that contribute to tumorigenesis in granulosa cells is required. Understanding the molecular pathogenesis of this disease will potentially provide novel targeted therapeutic options which will improve the survival rate of these patients.
function, that is, transcription factors GATA-4 and GATA-6, friend of GATA-2 (FOG-2), steroidogenic factor 1 (SF-1), Mü llerian inhibitory substance (MIS) and inhibin-a, in a GCT tissue microarray comprising 80 primary tumours. No significant differences in the immunoreactive levels of inhibin-a, GATA-6, FOG-2 or SF-1 were found in GCTs compared with normal granulosa cells. MIS expression was low (reduced) in 69% of GCTs and correlated inversely with tumour size. Whether large GCTs lose MIS expression at some point or display only low levels from the beginning remains unknown. In contrast, GATA-4 expression was equivalent to that seen in normal granulosa cells (classified as being high by the authors) in 44% GCTs and correlated positively with clinical stage and recurrence. GATA-4 immunostaining may serve as a prognostic tool; however, this would require further analyses, such as confirming the cut-off for immunoreactivity with a computerized scoring system in different patient sets [7] .
Juvenile granulosa cell tumour markers
The molecular phenotype of GCTs is consistent with activation of the FSH receptor signalling pathway [3, 6, 8] . The FSH receptor is a seven-transmembrane domain or G-protein-coupled receptor (GPCR). Signalling involves coupling with heterotrimeric G-proteins to activate intracellular second messenger systems, principally the cyclic AMP (cAMP)-dependant protein kinase A (PKA) pathway, but other pathways may also be activated [3] . The signalling pathway-generated cAMP was shown to be mitogenic in hormone-dependent endocrine tissues such as adrenal cortex, thyroid, ovary, pituitary and testes [9, 10] . These cell types receive extracellular signals via seven transmembrane receptors that are coupled to the adenylyl cyclase pathway through the G-protein, Ga s. Activating point mutations in Ga s involving the replacement of either arginine 201 (R201) or glutamine 227 (Q227) were first detected in pituitary growth hormone (GH)-secreting tumours and hyperfunctioning thyroid adenomas [11, 12] . The mutationally activated form of the gene encoding Ga s is known as the gsp (derived from Gs protein) oncogene. In these tumour types, the gsp oncogene product results in the constitutive activation of cAMP-dependent PKA signalling, which leads to abnormal cell proliferation [10] .
To date, no evidence of the gsp oncogene in adult GCTs has been reported [13] [14] [15] . The majority of patients with GCTs are adults but a rare juvenile form, occurring in prepubertal girls and young women, accounts for approximately 5% of all GCTs [16] . Kalfa et al. [17] recently reported the presence of the gsp oncogene in 30% (nine out of 30) of juvenile GCT cases. When compared with the patients with normal Ga s , the clinical symptoms and age of occurrence were not significantly different and patients carrying the mutation did not exhibit more severe hyperoestrogenic symptoms. They did, however, exhibit a more aggressive pattern of behaviour, with seven of the nine oncogenic gsp-positive patients presenting with stage Ic disease or developing recurrence. This indicates that the gsp oncogene may be a useful prognostic factor in juvenile GCTs [17] . We would suggest that constitutive activation of the PKA pathway is fundamental in juvenile GCTs and although the gsp oncogene is the cause of the constitutive activity in only 30% of these tumours, a mutation in other component(s) of the pathway may account for constitutive activation in the remaining 70% of tumours. The fact that this mutation is present in juvenile GCTs yet absent in adult GCTs is curious considering the tumours are otherwise phenotypically similar.
Another recent study by the same group reported extinction of Forkhead box L2 (FOXL2) protein expression in aggressive juvenile GCTs [18 ] . The FOXL2 gene comprises a single exon which encodes a forkhead/ winged helix transcription factor. It potentially regulates growth differentiation factor 9 (GDF9), inhibin bA (INHBA) and MIS expression and is required for both granulosa cell differentiation and development of ovarian follicles [19] . Patients carrying mutations in the FOXL2 gene display blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), an autosomal dominant disease associated with eyelid defects and premature ovarian failure in women [20] . Kalfa et al. [18 ] found the protein expression of FOXL2 to be absent or decreased in juvenile GCTs with an aggressive pattern of progression. Patients with no or reduced expression of FOXL2 more frequently had a higher mitotic activity in the tumour, hemorrhagic ascites and significantly more advanced disease at diagnosis. Thus loss of FOXL2 protein expression may also be a prognostic factor for these tumours [18 ] . Unfortunately the authors did not compare the findings of their two studies to determine whether a correlation exists between the gsponcogene, reduced FOXL2 protein expression and a more aggressive tumour type.
The inhibins and Mü llerian inhibitory substance as tumour markers
The inhibins consist of a dimer of two homologous subunits, an a subunit (made up of three regions, Pro, aN and aC) and either a bA or bB subunit, to form inhibin A and B, respectively. Subunit expression and secretion of a subunit monomers or ab subunit dimers appear to be independently regulated in the normal ovary. Inhibin B is predominantly produced by small developing follicles whereas inhibin A is primarily produced by the dominant follicle and corpus luteum [21, 22] . With the depletion of ovarian follicles at menopause, serum inhibin A and B decrease to very low or undetectable levels [23] , providing a good baseline to compare with serum levels in postmenopausal women with GCTs.
The first description of elevated serum inhibin levels in postmenopausal women with GCTs appeared in 1989 [24] . The initial observations that serum inhibin was elevated in GCTs were based on a serum radioimmunoassay, the so-called Monash assay, which detects all a subunitcontaining forms [25] . Subsequently, results of several studies utilizing specific enzyme-linked immunosorbent assays (ELISAs) to measure the individual forms of inhibin A and B showed that they were increased to varying extents in women with GCTs [26] [27] [28] . Robertson et al. [29 ] have recently summarized their experiences with the inhibin assays. They showed that the more specific assays for detecting serum inhibin A and B poorly discriminated between normal and cancer samples when compared with the Pro-aC (free a subunit) assays, whereas the total inhibin assay which detects all forms that contain the carboxy terminal (aC) region of the a subunit gave the best differentiation and was the preferred method [30, 31] .
Mom et al. [32 ] evaluated the clinical presentation, treatment and follow-up of 30 patients with GCTs and investigated the applicability of serum inhibin A and B levels for the assessment of disease status. The sensitivity of inhibin A testing for the diagnosis of GCTs was 67% (six out of nine) with a specificity of 100%, compared to 89% (eight out of nine) and 100%, respectively, for inhibin B. Serum inhibin A and B concentrations were elevated in 58% (seven out of 12) and 85% (11 out of 13) of patients, respectively, at recurrence, with elevations in inhibin B concentrations predating recurrences by a median of 11 months (range 8-19 months). No increases in serum inhibin A or B levels were observed in any of the 17 patients who remained disease-free following surgery [32 ] . Although these data support those of Petraglia et al. [28] , the increased specificity (and arguably sophistication) of these assays does not necessary translate into a clinical advantage when compared with the original assay [33] [34] [35] . Likewise, although inhibin B is the major form of inhibin secreted by GCTs, the value of an inhibin B-specific assay over a total inhibin assay remains questionable [29 ] .
Several studies investigating the dynamics of serum MIS, also referred to as anti-Mü llerian hormone (AMH), in patients with GCTs show it to be a reliable marker for tumour activity [36] [37] [38] [39] and were the focus of a recent review [40 ] . MIS is expressed by granulosa cells of the ovary during the reproductive age and controls the formation of primary follicles by inhibiting excessive follicular recruitment by FSH. Anttonen et al. [7] found MIS gene expression correlated inversely with GCT size, with reduced expression in 87% of tumours of greater than 10 cm in size. This finding may suggest MIS is a less useful marker than the inhibin assay in more advanced disease; however, to date there has been no direct comparison. Further studies are required to confirm whether total inhibin, inhibin B or MIS constitutes the more reliable marker in the detection and management of patients with GCTs.
Surgery and chemotherapy
Conventional treatment for GCTs has predominantly been with surgery followed by chemotherapy in which recurrent or advanced disease or both has occurred. Colombo et al.
[2] have recently reviewed in some detail the surgical approaches available. They conclude that there is a place for conservative surgery without hysterectomy in younger women [2] . This recommendation is borne out by the large retrospective analysis of Zhang et al. [4] , in which the results with conservative surgery did not differ from those using a standard surgery with hysterectomy. Current chemotherapy is based on platinum-containing protocols derived largely from experience with ovarian epithelial tumours [2]. These protocols have more recently also included taxanes [2].
Hormonal treatment
GCTs are often distinguished by their ability to secrete sex steroids, such as oestrogen, and thus there is an interest in evaluating hormonal manipulation as a potential therapeutic strategy.
Freeman and Modesitt [41] reported two patients with recurrent adult GCTs responding to the aromatase inhibitor, anastrozole. Each patient was initially treated with surgery alone. Following recurrence, they received multiple treatment modalities, including chemotherapy, the gonadotropin-releasing hormone (GnRH) agonist, leuprolide, and, in one case, local radiation. These therapies were discontinued after both patients' inhibin B levels continued to rise and anastrozole was initiated with subsequent normalization of inhibin B levels [41] . Hardy et al. [42] also reported a patient with oestrogen receptor-negative and progesterone receptor-positive GCT responding to biweekly cycles of megestrol and tamoxifen, remaining disease-free for 5 years. Conversely, studies of patients showing no response to hormonal therapies of medroxyprogesterone acetate, buserelin, tamoxifen or formestane [43] or a synthetic GnRH analogue [44] also exist.
Although a limited number of studies have demonstrated a response to hormonal treatment, confirmation in a larger cohort is required. Nevertheless, the mechanism of its action remains to be addressed. Indeed, it can be argued that a direct role for oestrogen in granulosa cell tumorigenesis is unlikely. Oestrogen receptor b is predominantly and abundantly expressed in GCTs, in contrast to oestrogen receptor a which shows moderate expression in GCTs and, indeed, in normal granulosa cells [45] . Furthermore, transrepression of oestrogen receptor b signalling by the constitutive and inducible activation of the nuclear factor (NF)-kB signalling pathway in two human GCT-derived cell lines, COV434 and KGN, suggests the role of oestrogen receptor b in GCT is likely to be antiproliferative [46] . The role of oestrogen receptor b as an antiproliferative factor in other cancer types, including breast, prostate and colon, has recently been reviewed [47] . Thus, if oestrogen action is relevant to tumorigenesis, it is likely to involve oestrogen receptor a which, in contrast to oestrogen receptor b, is expressed at low levels in GCT [45] . Therefore, we speculate oestrogen is more likely to be acting on the tumour environment, such as stroma or angiogenesis, rather than the tumour itself, if it does play a role.
Although the results with the aromatase inhibitors are intriguing [41, 43] , the numbers treated in these studies are too low to allow a conclusion to be drawn.
Tyrosine kinase inhibitors
A case study of a patient with advanced stage recurrent GCT responding to the tyrosine kinase inhibitor (TKI), imatinib mesylate [48] and constitutive activation of both NF-kB and activated protein-1 (AP-1) signalling in two human GCT-derived cell lines, COV434 and KGN [46] , prompted Chu et al. [49 ] to explore a potential role for receptor tyrosine kinase (RTK) targets in GCT therapeutics.
Imatinib mesylate (also known as Gleevec, Glivec, CGP57148B or STI-571; Novartis International AG, Basel, Switzerland) functions as a specific inhibitor by competitive inhibition of ATP binding to four members of the split-kinase domain family of RTKs, Bcr-Abl, CD117 (c-Kit), and the platelet-derived growth factor receptors (PDGFR-a and PDGFR-b). Selective inhibition of these RTKs blocks signal transduction, thereby affecting many of the processes involved in tumour growth, progression, metastasis and angiogenesis. This action therefore represents a new and promising approach to cancer treatment [50] .
Chu et al. [49 ] characterized the expression profiles of the genes of the known targets of imatinib in a panel of human GCT and examined the effect of imatinib and subsequently nilotinib (a second generation TKI, also known as AMN107), on the two cell lines, COV434 and KGN. All four kinases were expressed but at levels lower than those observed in premenopausal ovarian samples. Known activating mutations in c-Kit (exons 9-11) and PDGFRA (exon 18) were not found by direct sequencing. Both cell lines responded to imatinib and to nilotinib, showing dose-dependent decreases in cell proliferation and viability. These responses paralleled those observed in an imatinib-sensitive cell line, K562, but at approximately 240-fold and 1000-fold higher concentrations of imatinib and nilotinib, respectively, suggesting that GCTs, in general, are unlikely to respond to imatinib or nilotinib therapy. The response of the cell lines implies an 'off-target' effect, that is, imatinib inhibition of a tyrosine kinase other than the four characterized [49 ] . As the concentration of imatinib is increased, a range of tyrosine kinases is inhibited, including (Fms-like tyrosine kinase 3) FLT3, c-Fms, c-Src and the epidermal growth factor (EGF)-receptor family [50] . Given that overexpression of colony-stimulating factor with its receptor, c-Fms, in normal granulosa cells resulted in proliferation and tumorigenesis [51] , Chu et al. also examined the two GCT-derived cell lines for expression of c-Fms and FLT3. They found neither to be expressed in both cell lines and, wherever expressed, the levels were very low, indicating that c-Fms and FLT3 were unlikely to be mediating the response. Although the findings of this study suggest that the tyrosine kinases targeted by imatinib do not have a significant pathogenic role in GCTs, they do suggest that a TKI, of appropriate specificity, may represent a therapeutic option in the treatment of GCTs [49 ] .
Conclusion
Recent research progress has provided molecular markers that may prove to be useful prognostic factors in predicting disease aggression and recurrence in patients. Alternative GCT-specific treatments are needed if outcomes in advanced disease are to improve. Further research into the pathobiology of GCT is required as this may yield novel targets for molecular targeted therapies, thus improving the long-term survival rates of patients with recurrent disease.
